Fusion-negative rhabdomyosarcoma orthotopic tongue xenografts for study of invasion, intravasation and metastasis in live animals
S. M. Hammoudeh, Y. Ng, B.-R. Wei, T. Madsen, R. M. Simpson, R. Weigert, P. A. Randazzo
Abstract
PAX3/7 Fusion-negative rhabdomyosarcoma (FN-RMS) is a childhood mesodermal lineage malignancy with a poor prognosis for metastatic or relapsed cases. Towards achieving a more complete understanding of advanced FN-RMS, we developed an orthotopic tongue xenograft model for studies of molecular basis of FN-RMS invasion and metastasis. The behavior of FN-RMS cells injected into murine tongue was examined using in vivo bioluminescence imaging, non-invasive intravital microscopy (IVM), and histopathology and compared to the prevailing hindlimb intramuscular and subcutaneous xenografts. FN-RMS cells were retained in the tongue and invaded locally into muscle mysial spaces and vascular lumen. While evidence of hematogenous dissemination to the lungs occurred in tongue and intramuscular xenografts, evidence of local invasion and lymphatic dissemination to lymph nodes only occurred in tongue xenografts. IVM and RNA-seq of tongue xenografts reveal shifts in cellular phenotype and differentiation state in tongue xenografts. IVM also shows homing to blood and lymphatic vessels, lymphatic intravasation, and dynamic membrane protrusions. Based on these findings, the tongue orthotopic xenograft of FN-RMS is a valuable model for tumor progression studies at the tissue, cellular and subcellular levels providing insight into kinetics and molecular bases of tumor invasion and metastasis and, hence, new therapeutic avenues for advanced FN-RMS.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A dual readout embryonic zebrafish xenograft model of rhabdomyosarcoma to assess clinically relevant multi-receptor tyrosine kinase inhibitors
Joseph W. Wragg, Emma Gray, … Susanne A. Gatz·Frontiers in OncologyPeer-reviewed·May 21, 2025
- Fusion-negative Rhabdomyosarcoma 3D-organoids as an innovative model to predict resistance to cell death inducers
C. Savary, P. Huchede, … L. Broutier·bioRxiv·Sep 6, 2022
- A patient-derived xenograft model of FUS::TFCP2 intraosseous rhabdomyosarcoma reveals chemoresistance and differential sensitivity to ALK inhibitors
Shefali Chauhan, Kristen Jones, … Monika Ashok Davare·bioRxiv·Aug 6, 2026
- RUNX2 inhibition disrupts a PAX3::FOXO1-RUNX2 feed-forward loop and dismantles oncogenic gene programs in fusion-positive rhabdomyosarcoma
Elizabeth A. Mendes, Aanandi Munshi, … Corinne Mary Linardic·bioRxiv·Jul 21, 2025
- Differential cell-ECM interaction of rhabdomyosarcoma subtypes regulated by PAX3-FOXO1
Antonios Chronopoulos, Ivan Chavez, … JinSeok Park·The Journal of Cell BiologyPeer-reviewed·Apr 22, 2025
- Single-cell mapping of tumor heterogeneity in pediatric rhabdomyosarcoma reveals developmental signatures with therapeutic relevance
S. G. Danielli, E. Porpiglia, … B. W. Schäfer·bioRxiv·Apr 20, 2022